The crisis in recruitment for clinical trials in Alzheimer's and dementia: An action plan for solutions
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The purpose of this editorial is to articulate the framework for a strategy to overcome the crisis in participant enrollment, a problem that is poised to derail the first goal of the National Plan to Address Alzheimer's Disease—to prevent and effectively treat Alzheimer's disease by 2025. The first goal of the National Plan to Address Alzheimer's Disease (hereinafter, the Plan) is to prevent and effectively treat Alzheimer's disease by 2025. The development of interventions to delay the onset, or slow or halt the progress, of dementia remains the overarching strategy toward achieving this goal. Now the crucial question is how to accelerate the overall enterprise of therapy development, in alignment with this goal, to avert the economic and social havoc that will occur as ever-growing numbers of people develop dementia. The formulation and launch of various efforts to improve current paradigms of treatment discovery and development that will alter the progression of disease process is a high-priority challenge for the Plan, policy makers, and the scientific community at large. the identification of safe and effective drugs well-controlled and well-powered pivotal clinical trials recruitment of a large number of research participants for clinical trials Although it is feasible that additional funding will address the first two factors, it will not necessarily address the third and most important barrier to therapy development, participant recruitment. In fact, the substantial increases in research funding will likely further expand the need for already limited research participants. The challenges associated with current models of research and development for the treatment and prevention of dementia, and the question of how to improve the productivity of these efforts, have been extensively deliberated at several meetings organized by the Alzheimer's Association's Research Roundtable, the Alzheimer's Association International Conference, Clinical Trials on Alzheimer's Disease, the Advances in Alzheimer Therapy conferences, and the EU-US Task Force 1-7. These deliberations have examined contributors to the challenges, as well as potential solutions to the problems facing current therapy development efforts. Although much progress has been made in improving the efficiency of clinical research in dementia, for example by using genetic or biomarker screening for sample enrichment 8, one factor has not been adequately addressed: difficulty in recruiting study participants. Second only to lack of adequate research funding, difficulty in participant recruitment is perhaps the most significant major barrier to clinical research progress. Difficulty in participant recruitment is a major reason for both lengthening the duration of clinical trials and increasing their costs, thus reducing efficiency. The struggle to enroll participants is a long-standing problem, dating back at least to the mid-1990s 9, and is a widespread difficulty for most dementia clinical trials and longitudinal studies 10-13. This challenge will increase dramatically in the coming years. One of the unique problems facing the field is that few people with Alzheimer's or another dementing illness participate in clinical trials. There are a variety of reasons for this. First, few are eligible; only approximately 20% to 25% of people with Alzheimer's are eligible to participate in Alzheimer's trials 14. In addition, few are referred by their physicians to clinical trials, due to poor physician awareness, fatalism, loss of patient to trial, or geographic distance. Another important contributing factor is that many clinical trials in Alzheimer's and dementia are now seeking participants who are in either the prodromal or asymptomatic phases of disease 15. In 2011, the National Institute on Aging (NIA) and the Alzheimer's Association released new research guidelines for diagnostic criteria. These guidelines take into account the recognition that Alzheimer's disease is a process that develops over decades, with neuropathological events occurring many years before measurable symptoms appear, let alone become advanced enough to be considered dementia. In accordance with this understanding of the disease process, many new clinical trials are using genetic risk factors and biomarkers (particularly amyloid positron emission tomography imaging) to identify individuals at elevated risk for participation. Included among these are the Anti-Amyloid Treatment in Asymptomatic Alzheimer's study, the TOMMORROW trial, the Autosomal Dominant Alzheimer's Disease trial, the Generations study, and the Dominantly Inherited Alzheimer Network Trials Unit. Such trials have tremendous potential to slow or potentially even arrest the progress of the disease before it reaches the dementia stage. However, they present their own unique challenges for recruitment, as typically people in these early phases of the disease are unaware of their situation and are not treatment seeking. In
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obstacles and opportunities in Alzheimer’s clinical trial recruitment
Watson, J. L., Ryan, L., Silverberg, N., Cahan, V., & Bernard, M. A. (2014) · Health Affairs · doi:10.1377/hlthaff.2013.1314 · Cited by 204
Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.03.007 · Cited by 147
Self-citation
Cited by
Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
Verberk, I. M. W., Slot, R. E., Verfaillie, S. C. J., Heijst, H., Prins, N. D., van Berckel, B. N. M., Scheltens, P., Teunissen, C. E., & van der Flier, W. M. (2018) · Annals of Neurology · doi:10.1002/ana.25334 · Cited by 315
Gilmore‐Bykovskyi, A. L., Jin, Y., Gleason, C., Flowers‐Benton, S., Block, L. M., Dilworth‐Anderson, P., Barnes, L. L., Shah, M. N., & Zuelsdorff, M. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.09.018 · Cited by 295
Towards a future where Alzheimer’s disease pathology is stopped before the onset of dementia
van der Flier, W. M., de Vugt, M. E., Smets, E. M. A., Blom, M., & Teunissen, C. E. (2023) · Nature Aging · doi:10.1038/s43587-023-00404-2 · Cited by 220
Indorewalla, K. K., O’Connor, M. K., Budson, A. E., Guess (DiTerlizzi), C., & Jackson, J. (2021) · Journal of Alzheimer’s Disease · doi:10.3233/jad-201081 · Cited by 93
“For example, AD clinical trials focused on disease prevention seek to recruit cognitively intact participants who are at higher risk of AD as identified by genetic and biomarker studies [2, 6, 48].”
BackgroundInfluentialAshford, M. T., Raman, R., Miller, G., Donohue, M. C., Okonkwo, O. C., Mindt, M. R., Nosheny, R. L., Coker, G. A., Petersen, R. C., Aisen, P. S., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12640 · Cited by 51
Self-citation
Metadata
- Authors
- Fargo, K. N., Carrillo, M. C., Weiner, M. W., Potter, W. Z., & Khachaturian, Z.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2016-11
- Volume
- 12
- Issue
- 11
- Pages
- 1113-1115
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2554936118
- Cited by
- 123
- References
- 2
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The crisis in recruitment for clinical trials in Alzheimer's and dementia: An action plan for solutions. https://app.cochat.ai/papers/10.1016/j.jalz.2016.10.001
- The paper
- Fargo, K. N., Carrillo, M. C., Weiner, M. W., Potter, W. Z., & Khachaturian, Z. (2016). The crisis in recruitment for clinical trials in Alzheimer's and dementia: An action plan for solutions. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2016.10.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.